Project Grant K99MH144381
- The National Institute of Mental Health awarded The Leland Stanford Junior University $1,066,793 under the Mental Health Research Grants program (CFDA 93.242) on April 1, 2026, to develop and validate a personalized repetitive transcranial magnetic stimulation (rTMS) protocol for treatment-resistant depression using electrophysiological biomarkers. The award funds an R61/R33 phased study that will use early local TMS-evoked potentials (EL-TEPs)—measurements of prefrontal excitability—to...
- The National Institute of Mental Health awarded Brigham & Women's Hospital Inc. $863,825 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a double-blind, confirmatory efficacy trial comparing imaging-based targeting versus scalp-targeted accelerated transcranial magnetic stimulation (ATMS) for treatment-resistant major depressive disorder. The trial will enroll 120 participants to test whether imaging-targeted ATMS, using Stanford Accelerated...
- The National Institute of Mental Health awarded The Research Foundation for The State University of New York $437,125 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a preliminary positron emission tomography study quantifying the mechanism of transcranial magnetic stimulation in depression. The recipient, operating as Stony Brook University, will investigate the relationship between repetitive transcranial magnetic stimulation (rTMS)—an FDA-approved...
- The National Institute of Mental Health awarded Massachusetts General Hospital $453,750 under the Mental Health Research Grants program (CFDA 93.242) on September 1, 2026, to develop a closed-loop system for assessing target network engagement using concurrent transcranial magnetic stimulation and functional MRI. The recipient is developing a flexible radiofrequency coil array (the RF Cap) that enables functional MRI acquisition simultaneously with transcranial magnetic stimulation in a...
- The National Institute of Mental Health awarded The McLean Hospital Corporation $771,937 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate the synaptic mechanisms underlying intermittent theta burst stimulation (ITBS) as a treatment for major depressive disorder. The research examines whether ITBS, an FDA-cleared patterned form of transcranial magnetic stimulation delivered clinically to the dorsolateral prefrontal cortex, works by enhancing...
- The National Institute of Mental Health awarded The Trustees of The University of Pennsylvania $762,440 on April 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and validate a concurrent transcranial magnetic stimulation and functional MRI protocol for measuring the effects of continuous theta burst stimulation to the right dorsolateral prefrontal cortex on anxiety-related neural and behavioral responses. The protocol will assess TMS-evoked BOLD responses and...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (Massachusetts General Hospital) $629,733 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support research into the mechanisms of magnetic activation of neurons. The research combines engineering, electrophysiological recordings, and computational modeling to systematically study how induced electromagnetic fields...
- The National Institute of Mental Health awarded the Regents of the University of Minnesota $167,473 on January 2, 2026, for a project grant under the Mental Health Research Grants program (CFDA 93.242) to measure neuroplastic effects of oscillation-locked transcranial magnetic stimulation. The research addresses treatment-resistant major depressive disorder, which affects more than 30 percent of individuals with MDD who show no response to two or more antidepressant interventions. The project...
- This federal Project Grant award of $498,429, provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), supports research to identify the key factors that determine an individual's response to transcranial direct current stimulation (tDCS). The research aims to apply machine learning algorithms to a large, multimodal dataset of over 225 tDCS-fMRI sessions to determine which factors, such as baseline task performance, brain...
- The National Institute of Mental Health awarded The Leland Stanford Junior University $116,837 on May 4, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate theta burst stimulation delivered during sleep as a neuromodulation approach for treating depression. The research tests whether intermittent theta burst stimulation (ITBS) targeting the dorsolateral prefrontal cortex during non-rapid eye movement sleep produces superior prefrontal plasticity compared to...
The National Institute of Mental Health awarded Trustees of Dartmouth College $114,152 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support research determining and enhancing the cellular selectivity of transcranial magnetic stimulation using optical physiology and computational models. The funded research directly tests predictions about how transcranial magnetic stimulation (TMS)—an FDA-approved treatment for drug-resistant depression, obsessive-compulsive disorder, and migraine—alters activity across diverse neuron subtypes and circuits in the cerebral cortex. The investigator will use genetically encoded optical indicators to monitor subcellular and cellular responses to electric-field doses mimicking the local electric field induced by TMS. During the K99 phase, the research will determine how electric-field-driven subcellular voltage changes in cell bodies, axons, and dendrites depend on morphological features and membrane properties, and will characterize how excitatory and inhibitory neurons respond differentially to TMS-induced stimulation. Work will employ optical calcium and voltage indicators in ex vivo cortical brain slices, building on earlier postdoctoral training in cultured neurons, with co-mentorship from two faculty members. Performance occurs in Hanover, New Hampshire. The award period runs through September 2, 2026. The award is a Project Grant, a competitive research funding instrument under the K99/R00 Pathway to Independence program, supporting up to two years with no renewal option.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($114k) | 8/27/26 | ||
| Not listed | $114.2k | 8/13/26 |